Updated to clarify that J&J’s existing Codman Neuro neurovascular portfolio will also be included in the new Cerenovus business.
Johnson & Johnson (NYSE:JNJ) said yesterday that it’s medical device division is rolling the Pulsar Vascular and Neuravi acquisitions, as well as its existing Codman Neuro neurological portfolio, into a new neurovascular business dubbed Cerenovus.
The New Brunswick, N.J.-based healthcare giant said the new brand, unveiled at the annual meeting of the Society of NeuroInterventional Surgery in Colorado Springs, is derived from the Latin words for ‘new’ and ‘brain’ and will focus on hemorrhagic and ischemic stroke.
The business is being renamed in part to coincide with the company’s $1 billion divestiture of its Codman neurosurgery business to Integra Lifesciences.
“Our neurovascular business is evolving and Cerenovus reflects our bold new vision, positioning and priorities,” group chairman Shlomi Nachman said in prepared remarks. “Inspired by how quickly a stroke can affect a person’s mind and our commitment to reducing the devastating impact, Cerenovus aims to help physicians give stroke patients a new lease on life.”
J&J’s Codman Neuro unit paid an undisclosed amount last December for Pulsar Vascular and its PulseRider device for treating brain aneurysms. PulseRider is designed to shore up the blood vessels around wide-necked aneurysms at or near a bifurcation of the basilar tip or carotid terminus and facilitate the implantation of an embolization coil, without obstructing blood flow through the vessels.
In April, the unit acquired Neuravi and its portfolio of neurovascular therapy technology, also for an undisclosed amount. Neuravi makes the EmboTrap and EmboTrap II revascularization platforms designed capture clots and allow blood flow to resume immediately after the clot has been secured in stroke patients.
